| Dr James Athanasius Macdonald V, MD | |
|
417 State St, Webber West, Suite 141, Bangor, ME 04401-6630 | |
| (207) 973-4670 | |
| (207) 973-4669 |
| Full Name | Dr James Athanasius Macdonald V |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 16 Years |
| Location | 417 State St, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558510792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD19475 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Thief River Falls | Thief river falls, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Health Network North | 8022206663 | 85 |
News Archive
The Office of Management and Budget released a statement on Tuesday warning that President Barack Obama would "veto the continuing resolution funding bill now being debated in the House if it contains drastic cuts to national security, but it remains unclear if large cuts in diplomacy and foreign aid programs would be enough to force White House action," Foreign Policy's blog "The Cable" reports.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.
Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The inability to manage weight gain and weight regain throughout life is helping to fuel the obesity epidemic in adults and children throughout Europe. However, the successful participation of more than 400 families in 8 countries in the largest European dietary intervention study, co-ordinated by the EC funded Diogenes project and headed by Professor Arne Astrup from the Faculty of Life Sciences at University of Copenhagen, is helping to address this vital issue.
› Verified 6 days ago
| Entity Name | Sanford Health Network North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386047355 PECOS PAC ID: 8022206663 Enrollment ID: O20180205002429 |
News Archive
The Office of Management and Budget released a statement on Tuesday warning that President Barack Obama would "veto the continuing resolution funding bill now being debated in the House if it contains drastic cuts to national security, but it remains unclear if large cuts in diplomacy and foreign aid programs would be enough to force White House action," Foreign Policy's blog "The Cable" reports.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.
Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The inability to manage weight gain and weight regain throughout life is helping to fuel the obesity epidemic in adults and children throughout Europe. However, the successful participation of more than 400 families in 8 countries in the largest European dietary intervention study, co-ordinated by the EC funded Diogenes project and headed by Professor Arne Astrup from the Faculty of Life Sciences at University of Copenhagen, is helping to address this vital issue.
› Verified 6 days ago
| Entity Name | Sanford Health Network North |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1043218753 PECOS PAC ID: 8022206663 Enrollment ID: O20180222001872 |
News Archive
The Office of Management and Budget released a statement on Tuesday warning that President Barack Obama would "veto the continuing resolution funding bill now being debated in the House if it contains drastic cuts to national security, but it remains unclear if large cuts in diplomacy and foreign aid programs would be enough to force White House action," Foreign Policy's blog "The Cable" reports.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.
Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The inability to manage weight gain and weight regain throughout life is helping to fuel the obesity epidemic in adults and children throughout Europe. However, the successful participation of more than 400 families in 8 countries in the largest European dietary intervention study, co-ordinated by the EC funded Diogenes project and headed by Professor Arne Astrup from the Faculty of Life Sciences at University of Copenhagen, is helping to address this vital issue.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Athanasius Macdonald V, MD 417 State St, Webber West, Suite 141, Bangor, ME 04401-6630 Ph: (207) 973-4670 | Dr James Athanasius Macdonald V, MD 417 State St, Webber West, Suite 141, Bangor, ME 04401-6630 Ph: (207) 973-4670 |
News Archive
The Office of Management and Budget released a statement on Tuesday warning that President Barack Obama would "veto the continuing resolution funding bill now being debated in the House if it contains drastic cuts to national security, but it remains unclear if large cuts in diplomacy and foreign aid programs would be enough to force White House action," Foreign Policy's blog "The Cable" reports.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.
Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The inability to manage weight gain and weight regain throughout life is helping to fuel the obesity epidemic in adults and children throughout Europe. However, the successful participation of more than 400 families in 8 countries in the largest European dietary intervention study, co-ordinated by the EC funded Diogenes project and headed by Professor Arne Astrup from the Faculty of Life Sciences at University of Copenhagen, is helping to address this vital issue.
› Verified 6 days ago
Murray Dana Lebowitz, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 417 State St, Webber West Suite 141, Bangor, ME 04401 Phone: 207-973-4670 Fax: 207-973-4661 | |
Dr. Farbod Nabizadeh, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 12 Stillwater Ave, Unit 1, Bangor, ME 04401 Phone: 207-945-6588 | |
Dr. Alec Anderson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 417 State Stree, Webber West Suite 141, Bangor, ME 04401 Phone: 734-936-9434 Fax: 734-232-6020 | |
Jane N. Laeger, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 700 Mount Hope Ave, Ste 430, Bangor, ME 04401 Phone: 207-947-8658 Fax: 207-947-4440 | |
Dr. Christopher Alan Rumsey, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Mount Hope Ave Ste 480, Bangor, ME 04401 Phone: 207-990-1615 Fax: 207-990-0693 | |
Dr. Garrick James Slate, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 417 State St, Suite 141, Bangor, ME 04401 Phone: 207-973-4670 Fax: 207-973-4669 | |
Paola Rinaldi-whitham, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 417 State St, Webber West Suite 141, Bangor, ME 04401 Phone: 207-973-4670 Fax: 207-973-4661 |